Page 34 - 《中国药房》2025年6期
P. 34

金丝桃苷调控肝脏脂质合成改善小鼠非酒精性脂肪性肝病的机

          制研究
                     Δ


          龙昌锐    1, 2* ,乡世健 ,张振华 ,吴辉星 ,周本杰 ,鲁澄宇 (1.广东医科大学药学院,广东 东莞 523808;
                                               2, 3
                                                         2, 3
                            2, 3
                                      2, 3
                                                                  1 #
          2.深圳市中药活性物质筛选与转化重点实验室,广东 深圳 518107;3.中山大学附属第七医院药学部,广东
          深圳 518107)
          中图分类号  R965;R575      文献标志码  A      文章编号  1001-0408(2025)06-0668-06
          DOI  10.6039/j.issn.1001-0408.2025.06.05


          摘   要  目的  研究金丝桃苷(HYP)对非酒精性脂肪性肝病(NAFLD)的改善作用机制。方法  将雄性C57BL/6小鼠随机分为正
          常(NFD)组、模型(HFD)组、HYP组,每组8只。除NFD组外,其余组小鼠喂养HF60高脂饲料诱导NAFLD模型,同时HYP组小鼠
          每日灌胃100 mg/kg的HYP,持续16周。末次给药16 h后,记录各组小鼠体重、肝脏质量,观察肝脏病理形态学变化及脂质堆积情
          况,检测肝脏中甘油三酯(TAG)含量和血清中TAG、天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)含量;采用液相色谱-串联质谱
         (LC-MS/MS)法检测小鼠肝脏的脂质变化,进行脂质组学分析,并检测脂质合成相关蛋白过氧化物酶体增殖物激活受体α(PPARα)
          蛋白的表达情况。将人源肝癌细胞株HepG2分为正常对照组、模型组、HYP低浓度(50 μmol/L)组、HYP高浓度(100 μmol/L)组、
          HYP低浓度+GW6471(PPARα抑制剂)组和HYP高浓度+GW6471组,除正常对照组外,其余细胞采用油酸、棕榈酸诱导构建高脂
          细胞模型,观察各组细胞脂滴蓄积情况,检测其中的TAG含量。结果  与HFD组比较,HYP组小鼠肝脏脂肪空泡、脂质堆积、肝脏
          质量和TAG含量,以及血清中ALT、AST、TAG含量均明显减少,肝组织中PPARα蛋白表达水平显著升高(P<0.05);NAFLD病理
          形态学变化均有所缓解。脂质组学分析发现HYP能降低肝脏中TAG、二酰甘油等脂质代谢物的相对水平。与模型组比较,HYP
          低、高浓度组细胞中脂滴蓄积和TAG含量均明显减少,GW6471能显著逆转HYP对上述指标的改善作用(P<0.05)。结论  HYP
          可有效改善高脂饲料诱导的小鼠NAFLD,其机制可能与激活PPARα从而调控肝脏脂质合成有关。
          关键词  金丝桃苷;非酒精性脂肪性肝病;脂质合成;脂质组学;PPARα

          Study  on  the  mechanism  of  hyperoside  regulating  hepatic  lipid  synthesis  to  ameliorate  non-alcoholic  fatty
          liver disease in mice
          LONG Changrui ,XIANG Shijian ,ZHANG Zhenhua ,WU Huixing ,ZHOU Benjie ,LU Chengyu                   1
                                                                             2, 3
                                                                                              2, 3
                         1, 2
                                                              2, 3
                                           2, 3
         (1.  School  of  Pharmacy,  Guangdong  Medical  University,  Guangdong  Dongguan  523808,  China;2.  Shenzhen
          Key  Laboratory  of  Active  Substances  Screening  and  Transformation  of  Traditional  Chinese  Medicine,
          Guangdong  Shenzhen  518107,  China;3.  Dept.  of  Pharmacy,  the  Seventh  Affiliated  Hospital  of  Sun  Yat-sen
          University, Guangdong Shenzhen 518107, China)

          ABSTRACT     OBJECTIVE To investigate the improvement mechanism of hyperoside (HYP) on non-alcoholic fatty liver disease
         (NAFLD).  METHODS  Male  C57BL/6  mice  were  randomly  divided  into  normal (NFD)  group,  model (HFD)  group  and  HYP
          group, with 8 mice in each group. Except for NFD group, the mice in other groups were fed with HF60 high-fat diet to establish
          NAFLD  model;  HYP  group  was  simultaneously  given  HYP  100  mg/kg  intragastrically  every  day,  for  16  consecutive  weeks.  The
          body weight and liver weight of mice in each group were recorded 16 h after the last medication; the histopathological changes and
          lipid  accumulation  in  the  liver  were  observed,  and  the  contents  of  triglyceride (TAG)  in  liver  tissue  and  serum  contents  of TAG,
          aspartate  transaminase (AST)  and  alanine  transaminase (ALT)  were  measured;  LC-MS/MS  method  was  adopted  to  detect  lipid
                                                              changes in the liver tissue of mice for lipidomics analysis, and
              Δ 基金项目 国家自然科学基金项目(No.82074078);广东省基础            protein  expressions  of  lipid  synthesis-associated  proteins
          与应用基础研究基金项目(No.2022A1515220027);深圳市科技计划项            peroxisome  proliferator-activated  receptor  α (PPARα)  were
          目(No.ZDSYS20220606100801003)                        also  tested.  Human  hepatocellular  carcinoma  cell  line  HepG2
             *第一作者 硕士研究生。研究方向:代谢组学与肝纤维化。E-
                                                              was  divided  into  normal  control  group,  model  group,  HYP
          mail:LongChR@gdmu.edu.cn
              # 通信作者 教授,硕士生导师,博士。研究方向:药效学与药代动                 low-concentration  group (50  μmol/L),  HYP  high-concentration
          力学。E-mail:luchengyu@gdmc.edu.cn                     group (100  μmol/L),  HYP  low-concentration+GW6471 (PPARα


          · 668 ·    China Pharmacy  2025 Vol. 36  No. 6                               中国药房  2025年第36卷第6期
   29   30   31   32   33   34   35   36   37   38   39